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Background: Approximately 30% of patients treated with cardiac resynchronization therapy (CRT) do not achieve
favourable response. The purpose of the present study was to identify echocardiographic and clinical predictors of
a positive response to CRT.
Methods: The study included 82 consecutive heart failure (HF) patients in New York Heart Association (NYHA)
functional class III or IV with left bundle branch block (LBBB), QRS duration ≥ 120 ms and left ventricular ejection
fraction (LVEF) ≤ 35%. Statistical analysis was performed using IBM SPSS statistical software (SPSS v.21.0 for Mac OS
X). A p value < 0.05 was considered statistically significant.
Results: Echocardiographic response was established in 81.6% and clinical response was achieved in 82.9% of
patients. Significant univariate predictors of favourable echocardiographic response after 12 months were smaller left
ventricular end-diastolic diameter (LVEDD) (odds ratio [OR] 0.89; 95% confidence interval [CI] 0.82 - 0.97, p = 0.01), and
smaller left ventricular end-systolic diameter (LVESD) (OR 0.91; 95% CI 0.85 - 0.98, p = 0.01). Lower uric acid concentration
was associated with better echocardiographic response (OR 0.99; 95% CI 0.99 - 1.0, p = 0.01). Non-ischemic HF etiology
(OR 4.89; 95% CI 1.39 - 17.15, p = 0.01) independently predicted positive clinical response. Multiple stepwise regression
analysis demonstrated that LVEDD lower than 75 mm (OR 5.60; 95% confidence interval [CI] 1.36 - 18.61, p = 0.01) was
the strongest independent predictor of favourable echocardiographic response.
Conclusions: Smaller left ventricular end-diastolic and end-systolic diameters and lower serum uric acid concentration
were associated with better response to CRT. Left ventricular end-diastolic diameter and non-ischemic heart failure
etiology were the strongest independent predictors of positive response to CRT.
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Approximately 1 – 2% of the adult population in developed
countries have HF, and its prevalence rises to ≥ 10% in
individuals 70 years of age or older [1]. Coronary artery
disease (CAD) is the cause of approximately two-thirds of
cases of systolic HF, although in many cases hypertension
and diabetes are likely contributing factors [2].
HF is associated with substantial mortality and
morbidity, and remains the most common hospital* Correspondence: diana.rinkuniene@gmail.com
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article, unless otherwise stated.discharge diagnosis in elderly patients. Development
of HF is characterised by progressive left ventricular
(LV) remodelling, that further impedes LVEF and is
responsible for progression of clinical symptoms. Results
from mechanistic studies, observational evaluations and
randomised controlled trials consistently demonstrated
significant improvement in quality of life, functional
status, and exercise capacity in HF patients in NYHA
class III and IV who were assigned to active CRT. However,
CRT does not provide any benefit to approximately
30% of patients [3-5]. Lack of response to CRT in
these studies may be in part attributed to inappropriate
echocardiographic and/or electrocardiographic criteria
used to select patients for CRT. The purpose of our studytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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parameters that predict positive response to CRT.
Methods
Patient population
The study included 82 consecutive HF patients, who
underwent CRT implantation at Cardiology Department
at Hospital of Lithuanian University of Health Sciences
Kaunas Clinics, between January 2009 and December
2011. All patients met the following inclusion criteria:
NYHA class III or IV despite optimal medical therapy,
LBBB, QRS width ≥ 120 ms and LVEF ≤ 35%. Patients
with previously implanted pacemaker or defibrillator, re-
cent myocardial infarction or coronary artery bypass graft
surgery (≤6 months), or decompensated HF were excluded.
Ischemic cardiomyopathy (ICMP) was diagnosed in
patients with previous myocardial infarction, or coronary
artery bypass graft surgery, or percutaneous coronary
intervention (balloon and/or stent angioplasty), or angio-
grafically documented significant coronary artery disease
and history of angina pectoris.
All patients were in sinus rhythm, electrocardiogram at
rest was recorded (measured on surface electrocardiogram
leads, at a paper speed of 25 mm/s) and QRS duration
was measured at baseline and after 12 months post CRT
implantation.
Clinical evaluation and two-dimensional echocardiog-
raphy were performed before CRT device implantation
and repeated at 12 months of follow-up. Clinical evaluation
included assessment of NYHA class and performance of
6 minute walk test (6-MWT). At 12 months of follow-up,
patients, who achieved improvement in NYHA of at least
1 class and a ≥ 15% increase in 6-MWT, were classified as
clinical responders.
Before the study all patients signed informed consent
approved by Local Ethics Committee (Kaunas Regional
Biomedical Research Ethics Committee, ref. n. BE-2-54).
Blood samples for uric acid concentration were taken
one to two days before CRT implantation and were
analysed in the laboratory of Lithuanian University of
Health Sciences Hospital Kaunas Clinics.
Two-dimensional echocardiography
Echocardiography was performed in all patients at rest
in the lateral decubitus position, at baseline before
device implantation and was repeated at 12-months
follow-up. Transthoracic Doppler echocardiography was
performed using a GE Vivid 7 system (GE Vingmed
Ultrasound AS N-3190, Horten, Norway) with an M4S
transducer. Standard transthoracic echocardiographic mea-
surements were performed according to the Guidelines of
the American Society of Echocardiography [6]. A standard
evaluation of LV volumes was performed, and LVEF
was calculated according to the Simpson’s equation. Tominimize variability of measurements, all echo/Doppler
evaluations were performed and analysed by the same
physician, also the same transducer position and sample
volume location were maintained throughout the record-
ings. All images were digitally stored for off-line analysis
(EchoPac V.6.0.0; GE Vingmed).
Echocardiographic response was defined as an increase in
LVEF of ≥ 5% and decrease of left ventricular end-systolic
volume (LVESV) and left ventricular end-diastolic volume
(LVEDV) by ≥ 15%.
Device implantation
CRT implantation was performed through the subclavian
or axillary vein access. Coronary sinus venogram was
obtained using balloon catheter. LV lead was inserted into
the posterolateral vein, which was selected according to
anatomical characteristics of the vessels enter the appropri-
ate electrode. The optimal position of the LV lead was
defined according to LV lead impedance, threshold and no
nervus phrenicus stimulation. The right atrial lead was
conventionally positioned in the right atrium appendage
and right ventricular lead in to the ventricular septum or
right ventricular apex. Finally, all leads were connected to a
dual chamber biventricular CRT device. The optimal atrio-
ventricular (AV) delay was determined during simultaneous
biventricular pacing by the simplified mitral inflow method:
a long AV interval (200 ms) was programmed and gradually
reduced by 20 ms, until A-wave truncation was observed.
Statistical analysis
Statistical analysis was performed using IBM SPSS statistical
software (SPSS v.21.0 for Mac OS X). Normally distributed
continuous variables were presented as mean ± SD and
were compared using Student t-test for paired and unpaired
data. Statistical significance of differences between groups
was analysed by Mann–Whitney U test for non-parametric
continuous variables and categorical variables were
compared using the maximum likelihood (ML) Chi-square
test. Correlation between continuous variables was analysed
by Spearman rank correlation test. Receiver operating
characteristic (ROC) curve was used to determine a cut-off
point of categorical predictors. Variables significant in uni-
variate analysis were added to logistic regression to deter-
mine independent predictors of response to CRT. Stepwise
variable selection with forward selection and backward
elimination demonstrated identical results. Precision of the
model was verified with the Hosmer-Lemeshow test of
goodness of fit test. A p value < 0.05 was considered statisti-
cally significant.
Results
Baseline characteristics of the subjects are summarized
in Table 1. A total of 82 consecutive patients were
included in the study. The study population consisted
Table 1 Baseline characteristics
Patient characteristics Baseline (n = 82)
Age (yrs.) 63.5 ± 10.5
Gender (male,%) 65 (79.3)
QRS duration (ms) 174.8 ± 17.0
NYHA class III n (%) 68 (82.9)
Six minute walk test (m) 300.8 ± 70.4
Diabetes n (%) 9 (10.8)
Hypertension n (%) 66 (80.5)
Paroxysmal AF n (%) 28 (34.5)
VT n (%) 25 (30.5)
CRT-D n (%) 36 (43.9)
LVEF (%) 20.3 ± 6.5
LVEDD (mm) 68.5 ± 9.7
LVESD (mm) 61.9 ± 10.0
LVEDV (ml) 220.6 ± 76.3
LVESV (ml) 175.3 ± 69.8
LAV (ml) 93.3 ± 28.5
Beta blockers n (%) 77 (93.9)
ACE-I n (%) 61 (74.4)
ARB n (%) 16 (19.5)
MRA n (%) 70 (85.4)
Diuretics n (%) 68 (82.9)
Amiodarone n (%) 24 (29.3)
Statin n (%) 40 (48.8)
Aspirin n (%) 29 (35.4)
Warfarin n (%) 27 (32.9)
Uric acid (μmol/l) 426.3 ± 133.2
NYHA - New York Heart Association, AF – atrial fibrillation, VT- ventricular
tachycardia, CRT-D – cardiac resynchronization therapy and defibrillator,
LVEF – left ventricular ejection fraction, LVEDD – left ventricular end-diastolic
diameter, LVESD - left ventricular end-systolic diameter, LVEDV - left ventricular
end-diastolic volume, LVESV - left ventricular end-systolic volume, LAV – left
atrial volume; ACE-I – angiotensin converting enzyme inhibitors; ARB -
angiotensin receptor blockers; MRA - mineralocorticoid receptor antagonists.
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63.5 ± 10.5 years. ICMP related HF was diagnosed in
37 (45.1%) patients. Most of the patients (82.9%) were
in NYHA class III. Mean 6-MWT was 300.8 ± 70.4 m.
CRT and defibrillator (CRT-D) were implanted in 36
(43.9%) patients, twenty-five of them had developed
paroxysmal monomorphic ventricular tachycardia (VT)
before implantation. According to inclusion criteria all
patients had a wide QRS complex (174.8 ± 17.0 ms), sinus
rhythm, LBBB configuration and were treated accord-
ing to HF guidelines [7], including beta-blockers,
angiotensin converting enzyme inhibitors (ACE-I) or
angiotensin receptor blockers (ARB), mineralocorticoid
receptor antagonists (MRA), and diuretics at maximum
tolerated doses.At 12 months of follow-up, a significant increase in
LVEF (mean 10.4 ± 7.6%, p < 0.001), significant reduc-
tion in LV diameters (LVEDD −10.7 ± 16.5 mm, p <
0.001, LVESD −6.7 ± 7.0, p < 0.001), LV volumes
(LVEDV −47.4 ± 53.7 ml, p < 0.001; LVESV −48.1 ± 50.2 ml,
p < 0.001) and left atrial volume (LAV) (−14.0 ml ± 19.0,
p < 0.001) were attained (Figure 1). In addition, a sig-
nificant increase in 6-MWT (from 300.8 ± 70.4 m to
405.5 ± 65.7 m; p < 0.001) and decrease in QRS duration
(from 174.8 ± 17.0 ms to 137.2 ± 15.0 ms; p = 0.001) were
observed.
Six patients died within 12 months of CRT implantation.
Due to the lack of full 12 month follow-up assessment,
data of these patients were not included into the analyses
of CRT response.
Clinical response
At 12 months follow-up 54 (71.1%) of patients had a
significant improvement in NYHA class (p < 0.001).
Distribution of NYHA class at baseline and after 12 months
post CRT implantation is provided in Figure 2. An increase
in 6-MWT by ≥ 15% was observed in 57 (75%) patients
(p = 0.001). Mean increase in 6-MWT post CRT was
121.2 ± 66.1 m in clinical responders and 11.3 ± 27 m
in non-responders (p = 0.001). Combined clinical response
(improvement in NYHA class ≥ 1 class and/or ≥ 15%
increase in the 6-MWT) was achieved in 63 (82.9%)
patients (Table 2).
Compared to responders, non-responders were more
likely to have ischemic cardiomyopathy (63.5% vs 36.5%,
p = 0.01). Echocardiographic response was observed in
87.3% combined clinical responders (p = 0.03).
Echocardiographic response
At 12 months of follow-up, LVEF increase of ≥ 5%
was observed in 81.6% patients. Increase in LVEF was
higher in patients with non-ICMP (11.2 ± 8.0 vs 7.7 ± 7.1;
p = 0.04). Combined echocardiographic response (LVEF
increase ≥ 5%, and/or LVESV decrease ≥ 15% and/or
LVEDV decrease ≥15%) was established in 81.6% of the
overall study population (Table 2). Compared to responders,
non-responders were more likely to have lower LVEF, larger
LVEDD, LVESD diameters and LV and LA volumes, AF
and VT episodes at baseline, although only LV diameters,
LAV, AF, VT achieved statistical significance (Table 3).
Also, a negative association of warfarin use and echo-
cardiographic response was found (p = 0.01). No signifi-
cant differences in QRS duration, gender, age and
CRT type between echocardiographic responders and
non-responders were found.
Significant univariate predictors of favourable echocar-
diographic response after 12 months included smaller
LVEDD (OR 0.89, 95% CI 0.82 - 0.97; p = 0.01) and
LVESD (OR 0.91, 95% CI 0.85 - 0.98; p = 0.01). Lower
78.6 ± 23.7* 
173 ± 66.7* 
124.4 ± 59.8* 
54.6 ± 10.5* 
61.4 ± 10.2*
31 ± 9.1* 
93.3 ± 28.5 
220.6 ± 76.3* 
175.3 ± 69.8 
61.9 ± 9.9 
68.5 ± 9.7 







Baseline After 12months 
Figure 1 Change in echocardiographic parameters during 12 months post CRT implantation (n = 76). *p < 0.001 between the same initial and
12 months follow up echocardiographic parameter. LVEF – left ventricular ejection fraction, LVEDD – left ventricular end-diastolic diameter, LVESD - left
ventricular end-systolic diameter, LVEDV - left ventricular end-diastolic volume, LVESV - left ventricular end-systolic volume, LAV – left atrial volume.
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http://www.biomedcentral.com/1471-2261/14/55uric acid concentration was associated with better
echocardiographic response (OR 0.99, 95% CI 0.99 - 1.0;
p = 0.01). The precision of the model was verified
with the Hosmer-Lemeshow test of goodness of fit
test (p = 0.1).Figure 2 Distribution of NYHA functional classes at baseline and afte
Heart Association.Non-ischemic HF etiology was an independent pre-
dictor of a positive clinical response (OR 4.89, 95%
CI 1.39 - 17.15; p = 0.01). The precision of the model was
verified with the Hosmer-Lemeshow test of goodness of
fit test (p = 0.49).r 12 months of CRT implantation (p = 0.001). NYHA - New York
Table 2 Clinical and echocardiographic response to CRT
at 12 months of follow-up
After 12 months (n = 76)
Combined echocardiographic response 62 (81.6%)
LVEF increase≥ 5% 62 (81.6%)
LVESV decrease≥ 15% 56 (73.7%)
LVEDV decrease ≥15% 55 (72.4%)
Combined clinical response 63 (82.9%)
NYHA improvement ≥ 1 functional class 54 (71.1%)
Six minute walk test ≥ 15% 57 (75%)
NYHA - New York Heart Association, LVEF – left ventricular ejection fraction, LVEDV -
left ventricular end-diastolic volume, LVESV - left ventricular end-systolic volume.
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analysis reached statistically significant cut-off values in
ROC analyses, with sensitivity ranging from 59% to 81%
and specificity from 61% to 77% (Figure 3).
Multiple stepwise regression analysis identified LVEDD
of less than 75 mm (OR 5.60, 95% CI 1.36 - 18.61; p = 0.01)Table 3 Comparison of echocardiographic and clinical param
and non-responders at baseline
Responders (n = 62)
LVEF (%) 21.2 ± 6.5
LVEDD (mm) 66.8 ± 9.8
LVESD (mm) 60.0 ± 10.0
LVEDV (ml) 211.0 ± 77.6
LVESV (ml) 166.4 ± 69.3
LAV (ml) 89.1 ± 30.2
QRS duration (ms) 174.5 ± 16.6
Six minute walk test (m) 305.6 ± 71.5
Age (yrs.) 63.2 ± 10.1
Gender (male,%) 51 (81)
Paroxysmal AF n (%) 18 (28.6)
VT n (%) 16 (25.4)
CRT-D n (%) 25 (39.7)
Beta blockers n (%) 61 (96.8)
ACE-I n (%) 48 (76.2)
ARB n (%) 13 (20.6)
MRA n (%) 52 (82.5)
Diuretics n (%) 51 (81)
Amiodarone n (%) 16 (25.4)
Statin n (%) 33 (52.4)
Aspirin n (%) 23 (36.5)
Warfarin n (%) 16 (25.4)
Uric acid (μmol/l) 397.7 ± 111.5
LVEF – left ventricular ejection fraction, LVEDD – left ventricular end-diastolic diame
end-diastolic volume, LVESV - left ventricular end-systolic volume, LAV – left atrial v
converting enzyme inhibitors, ARB - angiotensin receptor blockers, MRA - mineraloc
p value for the comparison between responders and non-responders.as the strongest independent predictor of favourable
echocardiographic response, and non-ischemic HF etiology
as the independent predictor of positive clinical response
(OR 4.88, 95% CI 1.39 - 17.15; p = 0.01).
Discussion
Prognosis of an HF patient depends on demographic,
echocardiographic, haemodynamic, neurohormonal, and
functional factors [8]. Each of these factors provided
powerful independent prognostic information, yet they
were poorly interrelated [9].
The present study confirmed that most patients
treated with CRT demonstrated favourable clinical and
echocardiographic responses during 12 months follow-up
period. The baseline LV diameters, uric acid concentration
and ischemic etiology were the main predictors of
response to CRT.
Echocardiographic response was related to outcomes,
but it was not associated with symptoms or quality of life.
Dominique Auger et al. [10] reported NYHA improvementeters between combined echocardiographic responders
Non-responders (n = 14) p value
17.9 ± 5.4 0.09
75.3 ± 6.5 0.01
68.4 ± 7.8 0.01
255.4 ± 50.6 0.05
201 ± 53.5 0.09
104.5 ± 17.6 0.02
175.7 ± 19.6 0.89
307.7 ± 57.3 0.72














506.3 ± 159.0 0.03
ter, LVESD - left ventricular end-systolic diameter, LVEDV - left ventricular
olume, AF – atrial fibrillation, VT- ventricular tachycardia, ACE-I – angiotensin
orticoid receptor antagonists.
Table 4 Echocardiographic and clinical parameters in the prediction of response to CRT
Area under curve
(AUC)
95% CI Sensitivity (%) Specificity (%) P value
LVEDD < 75mm 0.77 0.64 - 0.89 81 62 0.03
LVESD < 64mm 0.74 0.6 - 0.88 70 69 0.01
LAV< 90ml 0.70 0.57 - 0.83 59 77 0.03
Uric acid < 440μmol/l 0.69 0.53 - 0.86 71 61 0.03
CI – confidence interval, LVEDD – left ventricular end-diastolic diameter, LVESD - left ventricular end-systolic diameter, LAV – left atrial volume.
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response in 84% of patients. Similar results were obtained
in a study by Viviane Tiemi et al. [11], demonstrating
improvement in NYHA functional class in 79% of patients
after six months of CRT implantation. The 6-MWT was
used as a measure of response to CRT in a number of
studies, and was more sensitive compared to NYHA
functional class [12]. Our data did not contradict with the
findings of previous studies, as almost 82% of patients
achieved significant improvement in clinical and echocar-
diographic parameters. The need for complicated assess-
ment of CRT response is debatable, because from a
patient’s perspective improvement in clinical condition
matters most, hence changes in NYHA functional class
and six-minute walk distance may be unsophisticated and















Figure 3 ROC curve for the association of echocardiographic responsPrevious studies [13,14] demonstrated that patients
with ischemic heart disease had a lower likelihood of
response to CRT. Gasparini et al. [15] reported that
patients in the non-coronary artery disease (CAD) group
had a significantly greater increase in LVEF (p = 0.007)
and decrease in NYHA class (p < 0.05). Non-CAD
patients had a greater increase in LVEF and decrease in
NYHA functional class compared to patients with CAD.
Sylvain Reuter et al. [16] explained differences of response
according to etiology of HF, suggesting that left ventricular
pacing lead was not placed at the optimal site with
regard to ischemic areas. In contrast to our data and
previously discussed studies, Molhoek et al. [17] reported
no differences in CRT response in ischemic HF vs
idiopathic dilated cardiomyopathy groups. However, in this
study response to CRT was defined only by improvementecificity
1.00.80.6
rve
e and uric acid concentration. (AUC 0.69, p = 0.03).
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http://www.biomedcentral.com/1471-2261/14/55in NYHA functional class. In our study patients with
non-ICMP achieved a better clinical response compared
to ischemic patients (63.9% vs 36.1%, p = 0.009).
In this study, receiver-operating characteristic curve
analysis defined the optimal cut-off value of 64 mm for
LVESD and 75 mm for LVEDD to predict the response
to CRT, confirming previous analyses, [13,18] suggesting
the larger cardiac diameters are associated with poorer
response to CRT.
LA dilatation is a sensitive marker of chronic left heart
disease. Pressure and/or volume overload associated with
left ventricular involvement lead to gradual LA enlarge-
ment, electrical remodelling, and fibrosis. Considerable
evidence has been collected, demonstrating relationship
between increased LA size and cardiovascular morbidity
and mortality [19-21] in general population [22] and in
patients with left ventricular dysfunction [23,24]. In our
study, baseline LA volumes were substantially lower in
responders than in non-responders (89.1 ± 30.2 ml/m2 vs
104.5 ± 17.6 ml/m2, p = 0.02), and added to the prediction
of response to CRT. More research is needed to analyse
association of LA dilatation and response to CRT.
Higher uric acid concentration is associated with
increased risk of mortality and morbidity in patients
with HF [25,26]. Importance of uric acid in risk stratifi-
cation is recognized by the Seattle Heart Failure Model.
In our study, uric acid concentration was associated with
response to CRT, with possible multifactorial mecha-
nisms, i.e. increased xanthine oxidase activity induced
oxidative stress and inflammation, and renal dysfunction
related to hypoperfusion and diuretic therapy [25].
Further detailed studies are needed to define the exact
mechanism of the association of increased uric acid and
response to CRT.
In our study, there were no statistically significant
differences in medication use at baseline between
echocardiographic responders and non-responders,
except in warfarin use (p = 0.01). Indirect influence of
warfarin to the response to CRT might be explained by
the AF incidence (non-responders 61.5% vs responders
28.5%), or by larger left atrium and ventricular diameters
in non-responders.
Limitations of our study included a relatively small
sample size, single centre participation and short
study duration. Also, only patients with sinus rhythm
were enrolled, the proportions of genders in the study
were not equal.
Conclusions
Smaller left ventricular end diastolic and end systolic
diameters and lower serum uric acid concentration
were associated with better response to CRT. LVEDD and
non-ischemic HF etiology were the strongest independent
predictors of positive response to CRT.Competing interests
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